GlassScriptPhysician profile
Shayla Johnson
NPI 1962043075
$8,876.24
in general payments reported to CMS, 2019-2025
27 companies · $5,880 in 2025
The $5,880 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $502 · 2023: $153 · 2024: $2,002 · 2025: $5,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,033 · Travel and Lodging: $2,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,033.26 |
| Travel and Lodging | $2,001.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,441.46 | 2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $1,251.10 | 2025 | Optimizer |
| Boston Scientific Corporation | $968.70 | 2025 | Watchman, Watchman Flx |
| Amgen INC. | $812.75 | 2024-2025 | Repatha, Repatha |
| Medtronic, INC. | $513.28 | 2021-2023 | In.Pact Av, Arctic Front Advance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $488.61 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $448.01 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $308.26 | 2024-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $289.36 | 2022-2025 | Lokelma, Farxiga |
| Novo Nordisk INC | $238.98 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $214.73 | 2024-2025 | Verquvo, Capvaxive |
| Inspire Medical Systems, INC. | $203.74 | 2025 | Inspire |
| Recor Medical INC | $203.65 | 2024 | Paradise Renal Denervation System |
| Edwards Lifesciences Corporation | $193.65 | 2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.74 | 2022-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $155.30 | 2024 | |
| Atricure, INC. | $142.84 | 2024 | |
| Kestra Medical Technology Services, INC. | $136.29 | 2024-2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $131.15 | 2021-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $129.42 | 2024 | Opsumit, Uptravi |
| Abbott Laboratories | $108.51 | 2022 | |
| Tactile Systems Technology INC | $94.27 | 2024 | Entre Plus, Flexitouch Plus |
| Pfizer INC. | $68.98 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $50.54 | 2024 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $38.27 | 2025 | |
| Esperion Therapeutics, INC. | $37.06 | 2024 | Nexletol |
| Amarin Pharma, INC. | $27.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shayla Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.